Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Filippo de Marinis, Francesca Porta, Elena Guerini-Rocco, Carmine Valenza, Giuseppe Curigliano, Chiara Catania, Alessandra Rappa, Massimo Barberis, Giuseppe Viale
Publikováno v:
Current Oncology, Vol 28, Iss 292, Pp 3384-3392 (2021)
Current Oncology
Current Oncology
We present a case of a woman with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma who received gefitinib for 2 years and obtained a partial response. The patient then developed liver metastasis and a breast lesion, displaying high
Publikováno v:
Current Oncology, Vol 28, Iss 168, Pp 1803-1822 (2021)
Current Oncology
Current Oncology
Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine ther
Publikováno v:
Current Oncology, Vol 28, Iss 66, Pp 678-688 (2021)
Current Oncology
Volume 28
Issue 1
Pages 66-688
Current Oncology
Volume 28
Issue 1
Pages 66-688
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative
Publikováno v:
Current Oncology
Volume 19
Issue 5
Pages 1011-268
Volume 19
Issue 5
Pages 1011-268
Most women with advanced breast cancer will develop bone metastases, which are associated with the development of skeletal-related events (sres) such as pathologic fractures and spinal cord compression. This article reviews the evolving definition an
Publikováno v:
Current Oncology
Volume 19
Issue 11
Pages 1149-44
Volume 19
Issue 11
Pages 1149-44
New drugs such as pemetrexed, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, and the Alk inhibitor crizotinib have recently enabled progress in the management of advanced non-small-cell lung cancer (NSCLC). More drugs, especi
Autor:
Vera Hirsh
Publikováno v:
Current Oncology. 19:21-22
The Editor Current Oncology August 16, 2011 Re. Karam I, Melosky B. Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions. Curr Oncol 2012;19:(**COMP: add page range once known**).
Autor:
Barbara Melosky
Publikováno v:
Current Oncology
Volume 19
Issue 1
Pages 955-8
Volume 19
Issue 1
Pages 955-8
The systemic treatment options and algorithm for stage iv non-small-cell lung cancer have changed tremendously since 2005, leading to improved survival and quality of life for this group of patients. But the changes have also led to confusion and com